ArticlePloS one2019
Differentiation of hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic performance of artificial intelligence versus conventional imaging for differentiating G2/G3 from G1 pancreatic neuroendocrine tumors: a systematic review and meta-analysis.BMC medical imaging · 2026Pooled it
- Radiomics in differential diagnosis of pancreatic tumors.European journal of radiology open · 2025Article
- Morphological characterization of atypical pancreatic ductal adenocarcinoma with cystic lesion on DCE-CT: a comprehensive retrospective study.BMC medical imaging · 2025Article
- Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients receiving peptide receptor radionuclide therapy.Frontiers in endocrinology · 2025Article
- Quantitative evaluation of pancreatic neuroendocrine tumors utilizing dual-source CT perfusion imaging.BMC medical imaging · 2024Article
- Differentiating small (< 2 cm) pancreatic ductal adenocarcinoma from neuroendocrine tumors with multiparametric MRI-based radiomic features.European radiology · 2024Article
- Liver metastasized pancreatic neuroendocrine tumor in a 17-year-old female: A case report.Clinical case reports · 2024Article
- The radiomorphological appearance of the invasive margin in pancreatic cancer is associated with tumor budding.Langenbeck's archives of surgery · 2024Article
- Dual-energy CT improves differentiation of non-hypervascular pancreatic neuroendocrine neoplasms from CA 19-9-negative pancreatic ductal adenocarcinomas.La Radiologia medica · 2024Article
- Duodenal neuroendocrine neoplasms on enhanced CT: establishing a diagnostic model with duodenal gastrointestinal stromal tumors in the non-ampullary area and analyzing the value of predicting prognosis.Journal of cancer research and clinical oncology · 2023Article
- The value of enhanced CT features and texture-signatures in assessing the inflammatory infiltration of pancreatic ductal adenocarcinoma.Frontiers in oncology · 2023Article
- Pancreatic Neoplasms: CT Evaluation of the Uncommon Presentations of Common Lesions and Common Presentations of the Uncommon Lesions!The Indian journal of radiology & imaging · 2022Review
- MRI Feature-Based Nomogram Model for Discrimination Between Non-Hypervascular Pancreatic Neuroendocrine Tumors and Pancreatic Ductal Adenocarcinomas.Frontiers in oncology · 2022Article
- Computed tomography-based radiomics approach in pancreatic tumors characterization.La Radiologia medica · 2021Review
- Hypovascular pancreatic neuroendocrine tumor with hepatic metastases: A case report and literature review.Radiology case reports · 2021Article
- Factors associated with missed and misinterpreted cases of pancreatic ductal adenocarcinoma.European radiology · 2021Article
- Carcinoid Tumorlets Co-Existing with Chronic Pulmonary Inflammatory Processes: Imaging Findings and Histological Appearances.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Evaluation of Texture Analysis for the Differential Diagnosis of Mass-Forming Pancreatitis From Pancreatic Ductal Adenocarcinoma on Contrast-Enhanced CT Images.Frontiers in oncology · 2019Article
- Differentiation of chronic mass-forming pancreatitis from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography.Cancer management and research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypovascular pancreatic neuroendocrine tumors (hypo-PNETs) are often misdiagnosed as pancreatic ductal adenocarcinoma (PDAC). However, the treatment options and prognosis of PNETs and PDAC are substantially different. This retrospective study differentiated hypo-PNETs from PDAC using contrast-enhanced CT (CE-CT). Clinical data and CE-CT findings, including tumor location, size, boundary, pancreatic duct dilatation, local invasion or metastases, tumor contrast enhancement, and tumor-to-pancreas enhancement ratio, were compared between 39 PDACs and 18 hypo-PNETs. At CT imaging, hypo-PNETs showed a higher frequency of a well-defined margin and lower frequencies of pancreatic duct dilatation and local invasion or metastasis when compared with PDAC (p < 0.05 for all). The mean attenuation of hypo-PNETs at the arterial and portal venous phase was significantly higher than that of PDAC (p < 0.001, p = 0.003, respectively). Similar results were observed in tumor-to-pancreas enhancement ratio. Tumor attenuation and tumor-to-pancreas enhancement ratio at the arterial phase showed the largest area under the curve (AUC) of 0.888 and 0.812 with 83.3-88.9% of sensitivity and 61.6-77.0% of specificity. Pancreatic duct dilatation, local invasion or metastasis, and tumor attenuation at the portal venous phase also showed acceptable AUC (0.703-0.748). Thus CE-CT features, especially the enhancement degree at the arterial phases, may be useful for differentiating hypo-PNETs from PDAC using CE-CT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.